Ireland· IE-PA-PPA0465/320/001
Lopid 600 mg film-coated tablet
A gemfibrozil product containing gemfibrozil, registered in Ireland by PCO Manufacturing Ltd.. The same ATC class is registered in 12 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Gemfibrozil is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AB04 (gemfibrozil), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Gemfibrozil · ATC C10AB04
12 / 19 countries
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gemfibrozil costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gemfibrozil · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- FR France$0.50
- IT Italy$0.42
The record
At a glance
HPRA (Ireland)- Active substance
- Gemfibrozil
- Manufacturer
- PCO Manufacturing Ltd.
- Country
- Ireland (IE)
- ATC code
- C10AB04
- ATC class
- Gemfibrozil
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPPA0465/320/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
165 interactions on record for gemfibrozil.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemfibrozil · interactions on record
165 records
- 19 severe
- 57 moderate
- 2 minor
- 85 info
Most severe, free to view
- LoperamideA07DA03severe
- EluxadolineA07DA06severe
- PioglitazoneA10BG03severe
- RepaglinideA10BX02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gemfibrozil in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesGemfibrozilNCS HealthCare of KY, LLC dba Vangard Labs
- FinlandGevilonOrion Corporation Orion Pharma
- NetherlandsGemfibrozil Auro 600 mg, filmomhulde tablettenAurobindo Pharma B.V.
- SpainGEMFIBROZILO TARBIS 600 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTarbis Farma S.L.
- IcelandLopidPfizer ApS
- ItalyLOPIDPFIZER ITALIA S.R.L.
- United KingdomGemfibrozil 300mg capsulesKent Pharma (UK) Ltd
- NorwayLopidPfizer
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Gevilon
- Cyprus · Ipolipid, Lipofor
- Denmark · Lopid
- Spain · Gemfibrozilo Stada, Gemfibrozilo Tarbis
- France · Lipur
- United Kingdom (Northern Ireland) · Gemfibrozil Tillomed Laboratories, Lopid
- Greece · Fibrolip, Gemlipid
- Iceland · Lopid
- Italy · Gemfibrozil Doc Generici, Gemfibrozil Eg
- Netherlands · Gemfibrozil Aurobindo, Lopid
- Portugal · Gemfibrozil Generis, Lopid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e88a8ac9-ee28-4684-84ed-75fecad34e4a GET /v1/drugs/e88a8ac9-ee28-4684-84ed-75fecad34e4a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"C10AB",
"C10AB04"
],
"strength": null,
"pa_number": "PPA0465/320/001",
"substances": [
"Gemfibrozil"
],
"legal_basis": "Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC",
"market_info": "Unknown",
"authorised_at": "26/07/2013",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about gemfibrozil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.